SO-29 Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study

C Bakkers,F Van Erning,K Rovers,S Nienhuijs,J Burger,V Lemmens,A Aalbers,N Kok,D Boerma,A Brandt-Kerkhof,P Hemmer,W Van Grevenstein,P De Reuver,P Tanis,J Tuynman,I De Hingh

doi:10.1016/j.annonc.2020.04.044

SO-29 Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study

C Bakkers, F Van Erning + Show 14 more

Open Access

https://doi.org/10.1016/j.annonc.2020.04.044

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2020
License type: publisher-specific-oa

Affiliation: Catharina Ziekenhuis, Radboud University Nijmegen, Netherlands Comprehensive Cancer Organisation, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Dutch Cancer Society, Erasmus University Rotterdam, University Medical Center Groningen, University Medical Center Utrecht, University of Amsterdam, Vrije Universiteit Amsterdam

#Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy #Hyperthermic Intraperitoneal Chemotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In the Netherlands, limited variability exists in the performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This study offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.

Full Text